AMNIS News
Daily updated financial news for principal shareholders, family offices and ultra-high-net-worth clients.
Automatically updated · 21.07.2026 22:31
Yahoo Finance
Novartis AG (NVS) reports robust sales growth in priority brands like Kisqali and Kesimpta, while facing flat core operating income and margin pressures.
Open source→Yahoo Finance
Celcuity slides 15% despite FDA approval of Revtorpyk as investors focus on a late Q3 2026 launch that delays commercial sales and near-term revenues.
Open source→Yahoo Finance
Newer cancer medicines helped quarterly earnings reach $5.94 billion, while Novartis maintained its full-year guidance.
Open source→